ESMO Asia 2023 | Teslisotuzumab vedotin and osimertinib for EGFR-mutant, c-Met-overexpressing NSCLC

Hidehito Horinouchi, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, outlines the results of the Phase Ib trial (NCT02099058) testing osimertinib plus telisotuzumab vedotin in patients with advanced EGFR-mutant, c-Met-overexpressing non-small cell lung cancer (NSCLC) who progressed on osimertinib alone. With c-Met overexpression correlated with osimertinib resistance, the study pairs it with telisotuzumab vedotin, which targets c-Met directly. The overall and progression-free survival were beneficial and comparable to that of the highly successful MARIPOSA trial (NCT04487080). With a manageable safety profile, this treatment combination is promising. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.